Ono Pharmaceutical Management
Management criteria checks 3/4
Ono Pharmaceutical's CEO is Gyo Sagara, appointed in Sep 2008, has a tenure of 15.92 years. total yearly compensation is ¥190.00M, comprised of 41.1% salary and 58.9% bonuses, including company stock and options. directly owns 0.026% of the company’s shares, worth €1.56M. The average tenure of the management team and the board of directors is 1.6 years and 4.2 years respectively.
Key information
Gyo Sagara
Chief executive officer
JP¥190.0m
Total compensation
| CEO salary percentage | 41.1% |
| CEO tenure | 15.9yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.6yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | JP¥121b |
| Mar 31 2024 | JP¥190m | JP¥78m | JP¥128b |
| Dec 31 2023 | n/a | n/a | JP¥128b |
| Sep 30 2023 | n/a | n/a | JP¥125b |
| Jun 30 2023 | n/a | n/a | JP¥115b |
| Mar 31 2023 | JP¥228m | JP¥77m | JP¥113b |
Compensation vs Market: Gyo's total compensation ($USD1.29M) is below average for companies of similar size in the German market ($USD3.44M).
Compensation vs Earnings: Gyo's compensation has been consistent with company performance over the past year.
CEO
Gyo Sagara (66 yo)
15.9yrs
Tenure
JP¥190,000,000
Compensation
Mr. Gyo Sagara has been the Chief Executive Officer at Ono Pharmaceutical Co., Ltd since April 01, 2024 and serves as it’s Director and served as its President since September 2008 until April 01, 2024 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 15.9yrs | JP¥190.00m | 0.026% € 1.6m | |
| President | less than a year | no data | 0.0092% € 559.7k | |
| Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning | 1.1yrs | no data | no data | |
| Corporate Officer & Head of Risk and Compliance Management Department | 1.6yrs | no data | no data | |
| Managing Executive Officer | no data | no data | no data | |
| Corporate Officer & Head of Business Strategy Headquarters | 1.6yrs | no data | no data | |
| Ex. EO, Executive Dir. of Sus. Promotion Corp. Strategy & Planning and Representative Director | 1.6yrs | no data | 0.0060% € 364.1k | |
| Corporate Officer & Deputy Executive Director | no data | no data | no data | |
| Corporate Officer & Head of Medical Affairs | no data | no data | no data | |
| Managing Executive Officer & CMC / Production Division Chief | no data | no data | no data | |
| Head of Development Div. | no data | no data | no data |
1.6yrs
Average Tenure
60yo
Average Age
Experienced Management: ON4's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 18.2yrs | JP¥190.00m | 0.026% € 1.6m | |
| President | 4.2yrs | no data | 0.0092% € 559.7k | |
| Ex. EO, Executive Dir. of Sus. Promotion Corp. Strategy & Planning and Representative Director | 4.2yrs | no data | 0.0060% € 364.1k | |
| Independent Outside Director | 3.2yrs | no data | no data | |
| Outside Audit & Supervisory Board Member | 4.2yrs | no data | no data | |
| Outside Audit & Supervisory Board Member | 8.2yrs | no data | no data | |
| Audit & Supervisory Board Member | less than a year | no data | 0.0032% € 194.9k | |
| Independent Outside Director | 6.2yrs | no data | no data | |
| Independent Outside Director | 4.2yrs | no data | no data | |
| Chairman of Audit Supervisory Board | 3.2yrs | no data | 0.00043% € 26.3k |
4.2yrs
Average Tenure
60yo
Average Age
Experienced Board: ON4's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/14 17:41 |
| End of Day Share Price | 2024/05/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ono Pharmaceutical Co., Ltd. is covered by 24 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Aaron Ho | CFRA Equity Research |